The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.
 
Mansoor Raza Mirza
Leadership - Karyopharm Therapeutics; Sera Prognostics
Stock and Other Ownership Interests - Karyopharm Therapeutics; Sera Prognostics
Honoraria - Allarity Therapeutics; AstraZeneca; Geneos; Genmab/Seattle Genetics; GlaxoSmithKline; Merck; Mersana; Oncology Venture; Roche; Sotio; Takeda; Zai Lab
Consulting or Advisory Role - AstraZeneca; BioCad; Cerulean Pharma; Genmab; GlaxoSmithKline; Karyopharm Therapeutics; Pfizer; Sotio
Research Funding - Apexigen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Tesaro (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro
Other Relationship - European Network of Gynaecological Oncologic Trials; European Society for Gynaecological Oncology; Gynecological Cancer InterGroup
 
Matthew A. Powell
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline/Tesaro; GOG partners; Roche/Genentech; Seagen; Tesaro
Research Funding - GlaxoSmithKline/Tesaro (Inst)
 
Caroline Lundgren
No Relationships to Disclose
 
Vladyslav Sukhin
No Relationships to Disclose
 
Bhavana Pothuri
Honoraria - Bio Ascend; OncLive; PER; Projects in Knowledge
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Immunogen; Lilly; Merck; Mersana; Seagen; Signatera; Sutro Biopharma
Research Funding - Agenus (Inst); AstraZeneca (Inst); Celgene (Inst); Celsion (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); InxMed (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mersana (Inst); Novocure (Inst); NRG Oncology (Inst); Seagen (Inst); Sutro Biopharma (Inst); Takeda (Inst); Tesaro (Inst); Toray Industries (Inst); VBL Therapeutics (Inst)
Travel, Accommodations, Expenses - GOG Foundation; Merck; Seagen
Other Relationship - Society of Gynecologic Oncology
 
Lucy Gilbert
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Merck/Eisai
Consulting or Advisory Role - GlaxoSmithKline; Merck
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Esperas Pharma (Inst); Immunogen (Inst); IMV (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Roche (Inst); Tesaro/GSK (Inst)
 
Sarah Gill
No Relationships to Disclose
 
Graziana Ronzino
No Relationships to Disclose
 
Nicole Nevadunsky
No Relationships to Disclose
 
Stefan Kommoss
No Relationships to Disclose
 
Lyndsay Willmott
Consulting or Advisory Role - AstraZeneca; ImmunoGen
Speakers' Bureau - AstraZeneca; Eisai; ImmunoGen; Merck
 
Ingrid Boere
Consulting or Advisory Role - AstraZeneca (Inst); Tesaro/GSK (Inst)
Research Funding - GlaxoSmithKline (Inst)
 
Cara Amanda Mathews
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Deciphera (Inst); EMD Serono (Inst); Laekna Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst); Syros Pharmaceuticals (Inst); Tesaro/GSK (Inst)
 
Joseph Buscema
No Relationships to Disclose
 
Michael Teneriello
No Relationships to Disclose
 
Mark S. Shahin
Honoraria - AstraZeneca; GlaxoSmithKline; Seagen
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; ImmunoGen
Speakers' Bureau - AstraZeneca; Eisai; GlaxoSmithKline; Seagen
Research Funding - AstraZeneca; GlaxoSmithKline; Merck
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Seagen; Stryker
 
Oren Meyers
Employment - GlaxoSmithKline
 
Jamie Garside
Employment - GlaxoSmithKline
 
Robert L. Coleman
Employment - US Oncology
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Agenus; Alkermes; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; GOG Foundation; Gradalis; Immunogen; Karyopharm Therapeutics; Merck; Merck; Novocure; OncoMed; OncXerna Therapeutics
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); Immunogen (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (I)
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Brian M. Slomovitz
Consulting or Advisory Role - Agenus; AstraZeneca; Eisai; EQRx; Genentech; GlaxoSmithKline; GOG Foundation; Incyte; Lilly; Merck; Myriad Genetics; Nuvation Bio; Onconova Therapeutics; Onconova Therapeutics; Regeneron